Results 241 to 250 of about 353,583 (326)

Identification of a Novel Mutation in the SERPINE1 Gene Causing Clinical Hyperfibrinolysis in English Springer Spaniel Dogs

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background A 7‐month‐old female spayed English Springer Spaniel (ESS) was evaluated for spontaneous hemoperitoneum. Hyperfibrinolysis was identified on thromboelastography. Hypothesis/Objectives To identify a genetic mutation causing congenital hyperfibrinolysis in the proband and evaluate the prevalence of the mutation in the ESS breed ...
Kelley Kilpatrick, Jonah N. Cullen, Farah F. Almeer, LeeAnn Higgins, Todd Markowski, Marjory Brooks, Steven G. Friedenberg, Molly Racette   +7 more
wiley   +1 more source

Preoperative Prediction Models for 30‐Day All‐Cause Mortality After Mitral Valve Repair in Dogs: A Single‐Center Retrospective Cohort Study

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background Mitral valve repair (MVR) has emerged as a novel surgical intervention for dogs with myxomatous mitral valve disease (MMVD). However, no objective risk assessment method has been established for these cases. Objectives The primary aim of this study was to develop and evaluate preoperative prediction models for 30‐day postoperative ...
Shimon Furusato, Kentaro Kurogochi, Masashi Mizuno, Satoru Shinoda, Reo Tanoshima, Masami Uechi   +5 more
wiley   +1 more source

Retrospective Evaluation of Transcatheter Edge‐To‐Edge Mitral Valve Repair in Dogs With Myxomatous Mitral Valve Disease

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background Transcatheter edge‐to‐edge repair (TEER) is an emerging minimally invasive mitral valve repair treatment for dogs with myxomatous mitral valve disease (MMVD), but reports on its outcomes are limited. Objective Describe the clinical characteristics and complications in dogs with MMVD undergoing TEER.
Jeong‐Min Lee, Kyoung‐a Youp, Sun‐Tae Lee, Ah‐Ra Lee, Young‐Wook Cho, Youn‐Seo Jung, Jiwoong Her, Seung‐Keun Lee   +7 more
wiley   +1 more source

Significance of Lupus Anticoagulant in Children with Prolonged Prothrombin Time/activated Partial Thromboplastin Time

, 2016
Jeong Hyun Jo, Dong Woo Son, In Sang Jeon   +2 more
openalex   +1 more source

Continuous Renal Replacement Therapy: Application of Kidney Disease Improving Global Outcomes Guidelines for Treatment Prescription in Dogs With Acute Kidney Injury and Outcome Prediction

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background Continuous renal replacement therapy (CRRT) is routinely used in human patients with acute kidney injury (AKI) but studies in dogs are scarce. Objective To describe CRRT in dogs and assess the utility of a previously validated scoring system for dogs with AKI undergoing hemodialysis, and the Acute Patient Physiological and ...
Hilli Raskansky, Yaron Bruchim, Ran Nivy
wiley   +1 more source

Development and validation of a nomogram for circuit lifespan of regional citrate anticoagulation‐continuous renal replacement therapy in intensive care patients with acute kidney injury

Nursing in Critical Care, Volume 30, Issue 4, July 2025.
Abstract Background Regional citrate anticoagulation‐continuous renal replacement therapy (RCA‐CRRT) has a wide range of applications in clinical practice, but unplanned downtime due to RCA‐CRRT circuit coagulation is as high as 15.75%–66.70%. Aim To build a nomogram model for predicting the lifespan circuits of RCA‐CRRT.
Zhongbin Chen, Lingai Pan, Jia Zhang, Yanyu Chen, Yi Liu, Ping Jia, Shiya Liu, Bo Wang, Ping Zheng, Feng Chen, Bin Zeng, Wenting Zhang, Qin Yang, Xiaobo Huang, Caixia Xie   +14 more
wiley   +1 more source

Acute liver disorders in the third trimester—AFLP, HELLP and infectious hepatitis—update on pathology, diagnosis and management

The Obstetrician &Gynaecologist, Volume 27, Issue 3, Page 180-196, July 2025.
Key content The epidemiology and pathophysiology of AFLP, HELLP syndrome and infectious viral hepatitis in late pregnancy. Clinical presentation, diagnosis and management of these conditions. Complications (maternal and fetal) and how these can be managed. The role of a multidisciplinary team in management.
Victor N. Chilaka, Mohammed Bashir, Theodore Ngatchu, Badreldeen Ahmed, Justin C. Konje   +4 more
wiley   +1 more source

Clot formation and resolution properties of platelets during cold storage for 21 days

Transfusion, Volume 65, Issue 7, Page 1307-1318, July 2025.
Abstract Background Cold storage (2–6°C) preserves the aggregatory and clot formation properties of platelets beyond the standard 7‐day shelf life. Comparatively little is known about the effect of cold storage on clot resolution functions, which are necessary to ensure normal hemostatic balance is maintained.
Janhavi Mahajan, Matthew P. Padula, Denese C. Marks, Lacey Johnson   +3 more
wiley   +1 more source

Safety evaluation of the food enzyme AMP deaminase from the non‐genetically modified Aspergillus pallidofulvus strain AE‐DN

EFSA Journal, Volume 23, Issue 7, July 2025.
Abstract The food enzyme AMP deaminase (AMP aminohydrolase; EC 3.5.4.6) is produced with the non‐genetically modified Aspergillus pallidofulvus strain AE‐DN by Amano Enzyme Inc. The food enzyme was free from viable cells of the production organism. It is intended to be used in the processing of yeast and yeast products.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Jaime Aguilera, Magdalena Andryszkiewicz, Daniele Cavanna, Natália Kovalkovičová, Yi Liu   +17 more
wiley   +1 more source

Safety evaluation of the food enzyme aspergillopepsin I from the non‐genetically modified Aspergillus sp. strain AE‐PRHF

EFSA Journal, Volume 23, Issue 7, July 2025.
Abstract The food enzyme aspergillopepsin I (EC 3.4.23.18) is produced with the non‐genetically modified Aspergillus sp. strain AE‐PRHF by AMANO ENZYME INC. The food enzyme was free from viable cells of the production organism. It is intended to be used in 15 food manufacturing processes. Since residual amounts of food enzyme–total organic solids (TOS)
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Natália Kovalkovičová, Daniele Cavanna, Cristina Fernàndez‐Fraguas, Simone Lunardi, Silvia Peluso, Yi Liu   +18 more
wiley   +1 more source